Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.56 |
| ▸ | EYA3 | Q99504 | 5/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 7/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24221834 | 0.85 | SLC22A12 (0.57) | SLC22A12EYA3CYP2C9CYP2C19 | |
| SCHEMBL24102835 | 0.85 | SLC22A12 (0.51) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL26211225 | 0.84 | SLC22A12 (0.50) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL22680425 | 0.81 | SLC22A12 (0.44) | SLC22A12EYA3CYP2C9TTRCYP2C19 | |
| SCHEMBL22072520 | 0.80 | SLC22A12 (0.55) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL24103558 | 0.78 | SLC22A12 (0.57) | SLC22A12EYA3CYP2C9TTRCYP2C19 | |
| SCHEMBL24221837 | 0.75 | CYP2C19 (0.47) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL22680778 | 0.75 | CYP2C19 (0.60) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL25815944 | 0.74 | SLC22A12 (0.56) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL22680270 | 0.73 | SLC22A12 (0.57) | SLC22A12EYA3CYP2C9TTRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2021252630-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | SLC22A12 854/4885EYA3 4702/4885CYP2C9 482/4885 |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27B1, XDH, CYP27A1 | SLC22A12 830/4885EYA3 4761/4885CYP2C9 675/4885 |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ATP6V1B1, REN, CYP27B1 | SLC22A12 620/4885EYA3 3141/4885CYP2C9 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.